Publication: Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis
Issued Date
2018-09-02
Resource Type
ISSN
17512441
17512433
17512433
Other identifier(s)
2-s2.0-85052991756
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Review of Clinical Pharmacology. Vol.11, No.9 (2018), 903-916
Suggested Citation
Sermsiri Sangroongruangsri, Tanapat Ratanapakorn, Olivia Wu, Thunyarat Anothaisintawee, Usa Chaikledkaew Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis. Expert Review of Clinical Pharmacology. Vol.11, No.9 (2018), 903-916. doi:10.1080/17512433.2018.1507735 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46333
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis
Abstract
© 2018, © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Introduction: Anti-vascular endothelial growth factor (VEGF) therapy has become the most commonly used treatment for macular edema secondary to retinal vein occlusion (RVO). Although its superior efficacy as compared to other interventions has been proven, there is a lack of evidence for relative efficacy among anti-VEGF drugs. Areas covered: This work systematically reviewed and compared the efficacy of intravitreal bevacizumab, ranibizumab, and aflibercept for treating macular edema due to RVO. PubMed, EMBASE, and the Cochrane Library were searched from their inception until October 2017. Eleven randomized controlled trials (18 articles; 1830 adult patients) were identified. The proportion of patients who gained at least 15 letters in best-corrected visual acuity (BCVA), mean change from baseline in BCVA, and mean change from baseline in central macular thickness (CMT) were reported and these efficacy outcomes at 6 months were analyzed in network meta-analysis. Expert commentary: Apparently, bevacizumab, ranibizumab, and aflibercept were significantly superior to sham injection in terms of BCVA improvement and CMT reduction and had good safety profiles. However, there were no statistically significant differences in any outcomes among anti-VEGF drugs. In selecting an anti-VEGF drug for individual patients, other factors including affordability, drug availability, and patient characteristics should be considered.